Top Markets
Coin of the day
BioAge Labs Inc. BioAge Labs Inc.

BioAge Labs Inc.

BIOA
Classement en actions #15401
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Prix de l'action
$9.50
Capitalisation boursière
$357.48M
Changement (1 jour)
-0.05%
Changement (1 an)
92.60%
Pays
US
Échange BioAge Labs Inc. (BIOA)

Catégorie

Historique du prix de l'action pour BioAge Labs Inc. (BIOA)
Prix de clôture le plus élevé : $9.50 le 2026-09-01

Prix de clôture le plus bas : $20.04 le 2024-09-01
Historique du prix de l'action de BioAge Labs Inc. de 2024 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) 19.87%
2025 48.86%
2024 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
$548.98 40.40%
US
$1.03K 44.32%
NL
$121.37 -11.93%
AU
$144.39 499.38%
US
$748.60 4.92%
CH